{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:02:57Z","timestamp":1793084577874,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To identify drug-related problems (DRPs) associated with proton pump inhibitors (PPIs) and their influencing factors among hospitalized nephrology patients, thereby providing evidence for the rational use of PPIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of internal nephrology inpatients who received PPIs between June 2024 and May 2025 was assembled. Clinical pharmacists applied the PCNE classification system (version 9.1) to identify and categorize PPI-related DRPs. Univariate and multivariate logistic regression analyses were performed to explore factors contributing to inappropriate PPIs use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 520 patients were included, of which 241 patients (46.34%) experienced 303 DRPs. The most frequent problems involved drug selection and treatment duration. Multivariate analysis revealed that the following variables were independently associated with inappropriate PPIs use: purpose of PPI application (OR = 0.455, 95% CI 0.305\u20130.680,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), antiplatelet agents (OR = 1.552, 95% CI 1.062\u20132.268,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.023), anti-infective drugs (OR = 1.922, 95% CI 1.313\u20132.813,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001), and peritoneal dialysis (OR = 1.743, 95% CI 1.028\u20132.955,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.039).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systematic identification of PPI-related DRPs and analysis of their determinants by clinical pharmacists will substantially promote the rational use of PPIs in hospitalized patients with renal disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1776655","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:33:18Z","timestamp":1777527198000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of proton pump inhibitor-associated drug problems and contributing factors among hospitalized nephrology patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Ning","family":"Song","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Liangxiang Hospital of Beijing Fangshan District","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Liangxiang Hospital of Beijing Fangshan District","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/japtr.japtr_322_22","article-title":"A cross-sectional study on assessing depression among hemodialysis patients","volume":"13","author":"Albuhayri","year":"2022","journal-title":"J. Adv. Pharm. Technol. & Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2419851","DOI":"10.1001\/jamanetworkopen.2024.19851","article-title":"Agreement of different drug-drug interaction checkers for proton pump inhibitors","volume":"7","author":"Carollo","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/phar.70043","article-title":"Association of pneumonia, fracture, metabolic, and renal events with long-term proton pump inhibitor use in patients with chronic kidney disease","volume":"45","author":"Chien","year":"2025","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40620-020-00808-y","article-title":"Use of proton pump inhibitors in dialysis patients: a double-edged sword?","volume":"34","author":"Desbuissons","year":"2020","journal-title":"J. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jamda.2020.09.046","article-title":"The use and misuse of proton pump inhibitors: an opportunity for deprescribing","volume":"22","author":"Dharmarajan","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3949\/ccjm.81a.13070","article-title":"Do all hospitalized patients need stress ulcer prophylaxis?","volume":"81","author":"Eisa","year":"2014","journal-title":"Clevel. Clin. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/pds.3881","article-title":"The potential drug\u2013drug interaction between proton pump inhibitors and warfarin","volume":"24","author":"Henriksen","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.5056\/jnm23088","article-title":"Real-world prescription patterns and patient satisfaction regarding maintenance therapy of gastroesophageal reflux disease: an observational, cross-sectional, multicenter Study","volume":"29","author":"Huh","year":"2023","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1016\/s0041-1345(02)03409-7","article-title":"Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation","volume":"34","author":"Itagaki","year":"2002","journal-title":"Transplant. Proc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12882-023-03437-2","article-title":"Drug-related problems and associated factors among patients with kidney dysfunction at a tertiary hospital in southwestern Uganda: a prospective observational study","volume":"24","author":"Kyomya","year":"2023","journal-title":"BMC Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e747","DOI":"10.1093\/ajhp\/zxaf165","article-title":"Executive summary-society of critical care medicine and American Society of Health-System Pharmacists Guideline for the prevention of stress-related gastrointestinal bleeding in critically ill adults","volume":"82","author":"MacLaren","year":"2025","journal-title":"Am. J. Health-System Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ajg.2024.07.001","article-title":"The silent epidemic: inappropriate use of proton pump inhibitors among hospitalized patients","volume":"25","author":"Mohamed","year":"2024","journal-title":"Arab J. Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s11606-020-06425-6","article-title":"Reducing inappropriate proton pump inhibitors use for stress ulcer prophylaxis in hospitalized patients: systematic review of De-Implementation studies","volume":"36","author":"Orelio","year":"2021","journal-title":"J. General Intern. Med."},{"key":"B15","unstructured":"The PCNE classification V9.1\n          \n          \n          2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70279","DOI":"10.1111\/jep.70279","article-title":"Evaluation of potentially inappropriate prescriptions among the geriatric population in Tabuk, Saudi Arabia via the STOPP\/START criteria, version 3: a multicentric Study","volume":"31","author":"Prabahar","year":"2025","journal-title":"J. Eval. Clin. Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2147\/jmdh.S461180","article-title":"Potentially inappropriate medications in hospitalized older patients in Tabuk, Saudi Arabia using 2023 beers criteria: a retrospective multi-centric Study","volume":"17","author":"Prabahar","year":"2024","journal-title":"J. Multidiscip. Healthc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on De-Prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e69700","DOI":"10.7759\/cureus.69700","article-title":"Drug-Related problems among peritoneal dialysis patients: a 12-Year retrospective cohort Study","volume":"16","author":"Tay","year":"2024","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/imj.15601","article-title":"Proton\u2010pump inhibitor use and the risk of peritoneal dialysis associated peritonitis","volume":"53","author":"Walia","year":"2022","journal-title":"Intern. Med. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12916-017-0804-x","article-title":"When is proton pump inhibitor use appropriate?","volume":"15","author":"Yadlapati","year":"2017","journal-title":"BMC Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.17235\/reed.2019.6155\/2019","article-title":"The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China","volume":"111","author":"Ying","year":"2019","journal-title":"Rev. Espa\u00f1ola Enfermedades Dig."},{"key":"B25","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1186\/s12877-023-04557-y","volume":"23","author":"Zhang","year":"2023","journal-title":"Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventionsBMC Geriatr."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1875101","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:51:52Z","timestamp":1780991512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1776655"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1776655","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1776655"}}